insights_auto
Why is BMRN down 2.60%?
Dive Deeperchevron_right
BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$58.44
arrow_downward
-2.60%(-1.56) 1D
$58.28
arrow_downward
-0.28% (-0.16)bedtimeAfter hours
Closed: Oct 1, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$59.81
High
$60.16
Low
$58.39
Mkt. cap
11.31B
Avg. vol.
1.90M
Volume
2.08M
P/E ratio
157.55
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.24
Shares outstanding
193.57M
No. of employees
3K
Open
$59.81
High
$60.16
Low
$58.39
Mkt. cap
11.31B
Avg. vol.
1.90M
Volume
2.08M
P/E ratio
157.55
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.24
Shares outstanding
193.57M
No. of employees
3K
News stories
From web sources and news partners
Investing.com Canada
·
2 hours ago
Form 4 Biomarin Pharmaceutical Inc For: 1 October By Investing.com
TipRanks
·
6 hours ago
BioMarin’s Palynziq Desensitization Study Signals Effort to Protect Long‑Term PKU Revenue
Yahoo Finance
·
9 hours ago
The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)
Simply Wall Street
·
18 hours ago
BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com